Universität zu Köln

Koch, Elias A. T., Petzold, Anne, Wessely, Anja ORCID: 0000-0003-1940-5115, Dippel, Edgar, Gesierich, Anja, Gutzmer, Ralf, Hassel, Jessica C., Haferkamp, Sebastian, Kaehler, Katharina C., Knorr, Harald, Kreuzberg, Nicole, Leiter, Ulrike ORCID: 0000-0002-8019-1577, Loquai, Carmen, Meier, Friedegund ORCID: 0000-0003-4340-9706, Meissner, Markus ORCID: 0000-0002-5630-587X, Mohr, Peter ORCID: 0000-0002-7328-7407, Pfoehler, Claudia, Rahimi, Farnaz, Schadendorf, Dirk ORCID: 0000-0003-3524-7858, Schell, Beatrice, Schlaak, Max ORCID: 0000-0002-1663-8098, Terheyden, Patrick, Thoms, Kai-Martin, Schuler-Thurner, Beatrice, Ugurel, Selma ORCID: 0000-0002-9384-6704, Ulrich, Jens, Utikal, Jochen ORCID: 0000-0001-5316-0241, Weichenthal, Michael ORCID: 0000-0002-9060-4961, Ziller, Fabian, Berking, Carola ORCID: 0000-0003-0229-8931 and Heppt, Markus V. (2022). Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity. Cancers, 14 (3). BASEL: MDPI. ISSN 2072-6694

Full text not available from this repository.

Abstract

Simple Summary The era of immune checkpoint blockade (ICB) with nivolumab and pembrolizumab (anti-PD-1) alone or in combination with ipilimumab (anti-CTLA-4) has led to prolonged survival in patients with cutaneous melanoma (CM). However, the response to ICB is low in patients with uveal melanoma (UM). This retrospective multicenter study examines the effectiveness of re-induction with ICB in patients with metastatic UM. A re-induction was recorded when ICB treatment was initiated a second time after a first ICB treatment was discontinued due to resistance or toxicity. We compared two cohorts (re-induction of ICB vs. once-only ICB) and present evidence for the clinical activity of a re-induction with ICB in a small subgroup of patients. Re-induction with immune checkpoint blockade (ICB) needs to be considered in many patients with uveal melanoma (UM) due to limited systemic treatment options. Here, we provide hitherto the first analysis of ICB re-induction in UM. A total of 177 patients with metastatic UM treated with ICB were included from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of ICB re-induction, two cohorts were compared: patients who received at least one ICB re-induction (cohort A, n = 52) versus those who received only one treatment line of ICB (cohort B, n = 125). In cohort A, a transient benefit of overall survival (OS) was observed at 6 and 12 months after the treatment start of ICB. There was no significant difference in OS between both groups (p = 0.1) with a median OS of 16.2 months (cohort A, 95% CI: 11.1-23.8) versus 9.4 months (cohort B, 95% CI: 6.1-14.9). Patients receiving re-induction of ICB (cohort A) had similar response rates compared to those receiving ICB once. Re-induction of ICB may yield a clinical benefit for a small subgroup of patients even after resistance or development of toxicities.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Koch, Elias A. T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Petzold, Anne UNSPECIFIED UNSPECIFIED UNSPECIFIED Wessely, Anja UNSPECIFIED orcid.org/0000-0003-1940-5115 UNSPECIFIED Dippel, Edgar UNSPECIFIED UNSPECIFIED UNSPECIFIED Gesierich, Anja UNSPECIFIED UNSPECIFIED UNSPECIFIED Gutzmer, Ralf UNSPECIFIED UNSPECIFIED UNSPECIFIED Hassel, Jessica C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Haferkamp, Sebastian UNSPECIFIED UNSPECIFIED UNSPECIFIED Kaehler, Katharina C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Knorr, Harald UNSPECIFIED UNSPECIFIED UNSPECIFIED Kreuzberg, Nicole UNSPECIFIED UNSPECIFIED UNSPECIFIED Leiter, Ulrike UNSPECIFIED orcid.org/0000-0002-8019-1577 UNSPECIFIED Loquai, Carmen UNSPECIFIED UNSPECIFIED UNSPECIFIED Meier, Friedegund UNSPECIFIED orcid.org/0000-0003-4340-9706 UNSPECIFIED Meissner, Markus UNSPECIFIED orcid.org/0000-0002-5630-587X UNSPECIFIED Mohr, Peter UNSPECIFIED orcid.org/0000-0002-7328-7407 UNSPECIFIED Pfoehler, Claudia UNSPECIFIED UNSPECIFIED UNSPECIFIED Rahimi, Farnaz UNSPECIFIED UNSPECIFIED UNSPECIFIED Schadendorf, Dirk UNSPECIFIED orcid.org/0000-0003-3524-7858 UNSPECIFIED Schell, Beatrice UNSPECIFIED UNSPECIFIED UNSPECIFIED Schlaak, Max UNSPECIFIED orcid.org/0000-0002-1663-8098 UNSPECIFIED Terheyden, Patrick UNSPECIFIED UNSPECIFIED UNSPECIFIED Thoms, Kai-Martin UNSPECIFIED UNSPECIFIED UNSPECIFIED Schuler-Thurner, Beatrice UNSPECIFIED UNSPECIFIED UNSPECIFIED Ugurel, Selma UNSPECIFIED orcid.org/0000-0002-9384-6704 UNSPECIFIED Ulrich, Jens UNSPECIFIED UNSPECIFIED UNSPECIFIED Utikal, Jochen UNSPECIFIED orcid.org/0000-0001-5316-0241 UNSPECIFIED Weichenthal, Michael UNSPECIFIED orcid.org/0000-0002-9060-4961 UNSPECIFIED Ziller, Fabian UNSPECIFIED UNSPECIFIED UNSPECIFIED Berking, Carola UNSPECIFIED orcid.org/0000-0003-0229-8931 UNSPECIFIED Heppt, Markus V. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-697476
DOI:	10.3390/cancers14030518
Journal or Publication Title:	Cancers
Volume:	14
Number:	3
Date:	2022
Publisher:	MDPI
Place of Publication:	BASEL
ISSN:	2072-6694
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language RETREATMENT; IPILIMUMAB; NIVOLUMAB Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/69747